Gottlieb: FDA Would Be Subject To More White House Control Under A Second Trump Term

The former commissioner warned that the FDA likely would get very different treatment under a second Trump term than it got under a first. Gottlieb also discussed the need for legislation to help advance ‘n of 1’ drug regulation and how to communicate uncertainty in a wide-ranging interview.

Former FDA Commissioner Scott Gottlieb is interviewed at a 1 February Friends of Cancer Research Event
Former FDA Commissioner Scott Gottlieb was interviewed 1 February at a Friends of Cancer Research diagnostic policy event. • Source: Friends of Cancer Research/YouTube

The US Food and Drug Administration under a “Trump 2.0” is unlikely to be given the same independence from White House oversight that it enjoyed during Donald Trump’s initial term as president, said Scott Gottlieb, Trump’s first FDA commissioner.

“There was a little less adult supervision,” Gottlieb said of the Trump administration’s oversight of

More from Legislation

House Budget Bill Includes Delayed Orphan Fix, Also Risks Downstream Cell and Gene Coverage

 

The first two classes of negotiated drugs under the Inflation Reduction Act would not benefit from a rare disease adjustment House Republicans included in their reconciliation package.

Trump’s Rx Pricing Order: The Best-Case And Worst-Case Scenarios

 

US trade and tariff leverage might successfully push European and other countries to pay more for medicines, but if not, President Trump’s executive order includes potential US drug withdrawal and other options to entice industry to lower US prices.

EU Health Data Space May Speed Up R&D Through Access To Multi-Omics & Clinical Record Data

 

The European Health Data Space framework will allow companies to accelerate R&D processes and identify new molecular targets faster by facilitating centralized access to certain types of high-quality data, Finland’s Orion Pharma says.

EU Wants Industry To Define ‘Trade Secrets’ Under Health Data Sharing Regulation

 

The European Health Data Space Regulation is deliberately “vague” when it comes to defining trade secrets because the EU wants the pharma industry to make recommendations on safeguarding intellectual property, a policy officer for the European Commission says.

More from Pink Sheet

Global Pharma Guidance Tracker - April 2025

 

Stay up to date on regulatory guidelines from around the world with the Pink Sheet’s Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.

Medicare Negotiation Does Not Violate Due Process, Appeals Court Rules, Other Suits At Risk

 
• By 

Decision in AstraZeneca’s lawsuit against the Health and Human Services Department is a precedent-setting victory for the government and a blow to manufacturer efforts to block the price negotiation program.

Keep Talking: US FDA’s Beleaguered Biologics Center Remains Vital To Regenerative Medicine

 

Advisory committee for Capricor’s deriamocel planned, regenerative medicine advanced therapy designations proliferate for osteoarthritis, and the ranks of dual RMAT/breakthrough therapy designation holders grow.